Hepatitis C

Merck to pay $3.85B for hepatitis C drug developer

Merck & Co. will spend about $3.85 billion for Idenix Pharmaceuticals Inc., a small company developing hepatitis C medicines that, together with Merck's experimental drugs, could produce lucrative combo therapies ...

Jun 09, 2014
popularity not rated yet | comments 0

Latest Spotlight News